Evodenoson, formerly known as ATL313 and DE-112, is a potent and selective A(2A)AR agonist (A2A adenosine receptor agonist) in development for novel treatment for sepsis. ATL313 significantly reduced infarct size and improved LV contractility at the end of reperfusion assessed by LV dp/dt at a dose of 900 ng/Kg. ATL313, reduces inflammation and improves survival in murine sepsis models. References: Yago T, Tsukamoto H, Liu Z, Wang Y, Thompson LF, McEver RP. Multi-Inhibitory Effects of A2A Adenosine Receptor Signaling on Neutrophil Adhesion Under Flow. J Immunol. 2015 Oct 15;195(8):3880-9. doi: 10.4049/jimmunol.1500775. Epub 2015 Sep 9. PubMed PMID: 26355151; PubMed Central PMCID: PMC4592819.

纯度：≥98%

CAS：844873-47-8